Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer

Urology

Volumn 71, Issue 6, 2008, Pages 1181-1185

  Lainakis, George ^a   Nikos, Antoniou ^b   Gerassimos, Alivizatos ^a   Michael, Chrisofos ^a   Iraklis, Mitsoyiannis ^a   Konstantinos, Livadas ^a   Ioannis, Varkarakis ^a   Harilaos, Katsifotis ^c   Dimopoulos, Meletios A ^a   Bamias, Aristotelis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^c Polykliniki Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DOCETAXEL; DOXORUBICIN; KETOCONAZOLE; ONDANSETRON; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DISEASE; MALE; NAIL DISEASE; NEUTROPENIA; ONYCHOLYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STOMATITIS; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 44649119833     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.02.048     Document Type: Article

References (25)

1. Berthold D.R., Sternberg C.N., and Tannock I.F. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23 (2005) 8247-8252
2. Petrylak D.P., Tangen C.M., Hussain M.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
3. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
4. Calabrò F., and Sternberg C.N. Current indications for chemotherapy in prostate cancer patients. Eur Urol 51 (2007) 17-26
5. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 217 (2003) 1232-1237
6. Beekman K.W., Fleming M.T., Scher H.I., et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 4 (2005) 86-90
7. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110 (2007) 556-563
8. Rangel C., Matzkin H., and Soloway M.S. Experience with weekly doxorubicin (Adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 39 (1992) 577-582
9. Millikan R., Baez L., Banerjee T., et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol 6 (2001) 111-115
10. Sella A., Kilbourn R., Amato R., et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 4 (1994) 683-688
11. Ellerhorst J.A., Tu S.M., Amato R.J., et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3 (1997) 2371-2376
12. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15 (1988) 371-389
13. Logothetis C.J., and Chong C.D.K. Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer. In: Johnson D.E., and von Eschenbach A.C. (Eds). Systemic Therapy for Genitourinary Cancers (1989), Year Book Medical Publishers, Chicago 235-238
14. Torti F.M., Lum B., and Freiha F.S. Approaches to advanced prostate cancer at Stanford University. In: Johnson D.E., Logothetis C.J., and von Eschenbach A.C. (Eds). Systemic Therapy for Genitourinary Cancers (1989), Year Book Medical Publishers, Chicago 239-244
15. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
16. Torti F.M., Bristow M.R., Howes A.E., et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 99 (1983) 745-749
17. Trachtenberg J., Halpern N., and Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 130 (1988) 152-153
18. Pont A., Williams P.L., Azhar S., et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 142 (1982) 2137-2140
19. Blagosklonny M.V., Dixon S.C., and Figg W.D. Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines. J Urol 163 (2000) 1022-1026
20. Dixon S.C., Zalles A., Giordano C., et al. In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. Cancer Lett 113 (1997) 111-116
21. Siegsmund M.J., Cardarelli C., Aksentijevich I., et al. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151 (1994) 485-491
22. Tu S.M., Millikan R.E., Mengistu B., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 357 (2001) 336-341
23. Bubley G.J., Carducci M.A., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
24. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
25. Michels J., Montemurro T., Murray N., et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer. Cancer 106 (2006) 1041-1046